EU proposes GDP revisions to factor in falsified medicines directive and other advancements
This article was originally published in SRA
Executive Summary
The European Commission has proposed major amendments to its guidance on good distribution practices for human medicines to take into account the legislative changes introduced by the new EU directive on falsified medicines and distribution practice advancements in general1-3.